Cost Evaluation of Basiliximab Treatment for Renal Transplant Patients in Japan
Background: International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral(R)). We conducted a cost evaluation by applying international clinical results to standard Japanese medical practice. Objective: To evaluate the impact of basiliximab in renal transplant patients receiving conventional immunosuppressive therapy using cyclosporin and corticosteroids from the perspective of the healthcare payer in Japan. Study design: A decision tree model was developed, comprising seven pathways with key clinical events identified after the transplantation. The average first-year treatment costs after transplantation for patients treated with and without basiliximab were calculated using the model. A sensitivity analysis was done to measure the degree of influence of several criteria including the incidences of rejection, and rejection responding to steroid pulse therapy and antibody therapy. Methods: Estimates of key clinical events were derived from the international studies. Calculation of direct medical costs were made from the payers Main outcome measures and results: Basiliximab use produced an estimated saving of Yen315 Conclusions: If the cost of basiliximab is less than Yen315
In order to set up a list of libraries that you have access to,
you must first login
or sign up.
Then set up a personal list of libraries from your profile page by
clicking on your user name at the top right of any screen.